NYSE · PBH

Prestige Consumer Healthcare Inc.

$50.40 +$0.74 (+1.49%) 1D Pre-market

Key Metrics

$2.35B
Market cap
12.36×
P/E · TTM
$1.09B
Revenue · TTM
$190.30M
Net income
EPS · TTM $3.79
Dividend yield
Free cash flow $246.45M
Beta · 1Y 0.04
EBITDA · TTM $288.77M
Gross margin 54.7%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jun 3
    From its Feb 26 high, the share price fell 35%.

    Peak close $70.21 on Feb 26; trough close $45.44 on Jun 3. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -35%
  • May 14
    The stock moved -11.3% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 14
  • Apr 2
    The stock moved -9.0% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Apr 2

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$2.35B
Enterprise value$3.28B
Shares outstanding47.4M
52-wk range$42.62 – $76.67
Avg volume · 20D326.7K
Net cash −$930.09M
Book value / share$37.62
IndustryPharmaceutical Preparations
ExchangeNYSE
About Prestige Consumer Healthcare Inc.
IPO dateFeb 10, 2005
Employees890

Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E12.36
P/S2.16
P/FCF9.55
EV/EBITDA11.37
EV/Sales3.02
Graham №$56.66

Profitability

Gross 54.7%
Operating 23.7%
Net 17.5%
FCF 22.6%
ROE / ROIC 10.2% · 6.8%

Financial Health

Current ratio3.57
Quick ratio2.25
Debt / equity0.53
Debt / EBITDA 3.44
Net cash −$930.09M
Working capital$310.56M

Cash Flow · TTM

Operating CF $257.63M
Capex −$11.18M
Free cash flow $246.45M
Buybacks $156.28M
Dividends paid
Shareholder yield 6.6%

Piotroski F-Score

4 / 9
Middling fundamentals · 4 of 9 signals passing

Altman Z-Score

2.2
Grey zone (1.81–2.99) · monitor

Graham Number vs Price

$56.66 vs $50.40
Trades below classic defensive value — Graham-cheap
Fundamentals through 2025-12-31 · computed by TickerWolf from SEC filings